M&F LLP Ref: 3053-4107US2

Express Mail No. <u>EL 912/001 382 US</u>





†AFFIX CUSTOMER NO. LABEL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

UTILITY APPLICATION AND FEE TRANSMITTAL (37 C.F.R. §1.53(b))

Commissioner for Patents
Box Patent ApplicationWashington, D.C. 20231

Sir:


roomstor.rorsor

Transmitted herewith for filing is the patent application of


Inventor(s) names and addresses:

- (1) Michael A. BOWEN 7812 Polara Place Rockville, MD 20855 USA;
- (2) Yuli WU3 Susanna WayNewtown, PA 18940 USA;
- (3) Wen-Pin YANG
 25 Rutgers Lane
 Princeton, NJ 08540 USA;
- Joshua FINGER222 Woodland Parkway, Apt. 254San Marcos, CA 92069 USA;
- (5) Steven NADLER
 164 Neil Court
 Princeton, NJ 08540 USA;
- (6) Pamela CARROLL309 Trinity Court #10Princeton, NJ 08540 USA; and
- (7) John FEDER277 Dutchtown-Zion RoadBelle Mead, NJ 08540 USA


658947 v1



	Additional inventors are listed on a separate sheet
For:	POLYNUCLEOTIDE ENCODING AN ACTIVATED HUMAN T- LYMPHOCYTE-DERIVED PROTEIN RELATED TO UBIQUITIN CONJUGATING ENZYME
Enclos	ed Are:
<u>134</u> <u>4</u>	total pages of Application, including: page(s) of Specification page(s) of Claims page(s) of Abstract sheets of Formal Drawings (FIGS. 1A/1B-6); Informal Drawings page(s) of Declaration and Power of Attorney
	 ☐ Unsigned ☐ Newly Executed ☐ Copy from prior application ☐ Deletion of inventors including Signed Statement under 37 C.F.R. §1.63(d)(2)
	REQUEST AND CERTIFICATION UNDER 35 U.S.C. §122(b)(2)(B)(i) (form PTO/SB/35) As indicated on the attached Request and Certification, Applicant(s) certify that the invention disclosed in the attached application HAS NOT and WILL NOT be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. Applicant(s) therefore request(s) that the attached application NOT be published under 35 U.S.C. §122(b).
	Incorporation by Reference:
	The entire disclosure of the prior application, from which a copy of the combined Declaration and Power of Attorney is supplied herein, is considered as being part of the disclosure of the accompanying application and is incorporated herein by reference.
	Deletion of Inventors (37 C.F.R. §1.63(d) and §1.33(b)
	Signed statement attached deleting inventor(s) named in the prior application serial no, filed
	Microfiche Computer Program (Appendix)
\boxtimes	22 pages of Sequence Listing
\boxtimes	Computer readable disk containing Sequence Listing
	Statement under 37 C.F.R. §1.821(f) that computer and paper copies of the Sequence Listing are the same, 2 pages



	Assignment Papers (assignment recordation cover sheet and assignment document; total pages)			
	 ☐ A check in the amount of \$40.00 for recording the Assignment ☐ Charge the Assignment Recordation Fee to Deposit Account No. 13-4500, Order No ☐ Assignment Papers filed in the parent application Serial No. 			
	Certification of chain of title pursuant to 37 C.F.R. §3.73(b) Priority is claimed under 35 U.S.C. §119 for:			
	Application No(s), filed, in(country). Certified Copy of Priority Document(s) [] filed herewith filed in application Serial No, filed English translation document(s) [] filed herewith			
\boxtimes	filed in application Serial No, filed Priority is claimed under 35 U.S.C. §119(e) for:			
	Provisional Application U.S. Serial No. <u>60/308,706</u> , filed <u>July 30, 2001</u> and Provisional Application U.S. Serial No. <u>60/244,688</u> , filed <u>October 30, 2000</u> .			
	Information Disclosure Statement			
	 □ Copy of [] cited references □ PTO Form-1449 □ References cited in parent application Serial No, filed 			
	Related Case Statement under 37 C.F.R. §1.98(a)(2)(iii)			
-	A copy of related pending U.S. Application(s) Serial No(s):, filed, respectively, is attached hereto.			
	A copy of related pending U.S. Application(s) entitled,, filed to inventor(s), respectively, is attached hereto.			
	A copy of each related application(s) was submitted in parent application serial no, filed			
	Preliminary Amendment Preliminary Amendment (MPER 503)			
	Return receipt postcard (MPEP 503) This is a continuation divisional continuation-in-part of prior application			
	serial no, filed, to which priority under 35 U.S.C. §120 is claimed.			
	Cancel in this application original claims of the parent application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)			
	A Preliminary Amendment is enclosed. (Claims added by this Amendment have been properly numbered consecutively beginning with the number following the highest numbered original claim in the prior application).			
	2			



	The status of the parent application is as follows:							
	A Petition for Extension of Time and a Fee therefor has been or is being filed in the parent application to extend the term for action in the parent application until							
	A copy of the Petition for Extension of Time in the co-pending parent application is attached.							
	No Petition for Extension of Time and Fee therefor are necessary in the copending parent application.							
, 🗆	Please abandon the parent application at a time while the parent application is pending or at a time when the petition for extension of time in that application is granted and while this application is pending has been granted a filing date, so as to make this application co-pending.							
	Transfer the drawing(s) from the parent application to this application							
	Amend the specification by inserting before the first line the sentence: This is continuation divisional continuation-in-part of co-pending application Serial No, filed							
I. CA	CALCULATION OF APPLICATION FEE							
	Number Fi		Number Extra	Rate	Basic Fee \$740.00/370.00			
Total	Claims	18 – 20 =	0 x	\$18.00/ \$9.00	\$ 0.00			
Indep	endent Claims	4 - 3=	1 x	\$84.00/ \$42.00	\$ 84.00			
□м	ultiple Depende	nt Claims	If marked, add fee of \$280.00 (\$140.00) \$ 0.00					
-				TOTAL:	\$ <u>824.00.</u>			
	· · · · · · · · · · · · · · · · · · ·							
Small entity status is or has been claimed. Reduced fees under 37 C.F.R. §1.9 (f) p herewith \$								
A check in the amount of \$ 824.00 in payment of the application filing fees is attached.								
	Charge fee to Deposit Account No. <u>13-4500</u> , Order No A DUPLICATE COPY OF THIS SHEET IS ATTACHED.							
The Commissioner is hereby authorized to charge any additional fees which required for filing this application pursuant to 37 CFR §1.16, with the parer application, or credit any overpayment to Deposit Account No. 13-4500, Or 3053-4107US2. A DUPLICATE COPY OF THIS SHEET IS ATTACHED								

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: October 29, 2001

By:

Jeslie U. Serunian

Leslie A. Serunian Registration No. <u>35,353</u>

Correspondence Address:

(609) 252-4526 Facsimile

BRISTOL-MYERS SQUIBB COMPANY P.O. Box 4000 Route 206 and Provinceline Road Princeton, NJ 08543 (609) 252-4000 Telephone Mailing Address:

MORGAN & FINNEGAN, L.L.P. 345 Park Avenue New York, NY 10154-0053

(212) 758-4800 Telephone (212) 751-6849 Facsimile



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

M.A. BOWEN, Y. WU, W-P. YANG, J. FINGER, S. NADLER, P. CARROLL, J.

Applicant(s):

FEDER

Group Art Unit:

To Be Assigned

Serial No.:

To Be Assigned

Examiner:

To Be Assigned

Filed:

Herewith (October 29, 2001)

For:

Polynucleotide Encoding An Activated Human T-Lymphocyte-Derived Protein

Related To Ubiquitin Conjugating Enzyme

EXPRESS MAIL CERTIFICATE

Express Mail Label No.:

EL 912 001 382 US

Date of Deposit:

October 29, 2001

I hereby certify that the following attached paper(s) and/or fee

1. Utility Application and Fee Transmittal (37 CFR 1.53(b)), (5 pages);

2. Utility Patent Application containing: 139 total pages of application, including 134 pages of Specification, 4 pages of Claims, 1 page of Abstract, 9 sheets Formal Drawings (FIGS. 1A/1B-6);

3. Sequence Listing (22 pages);

4. Statement Accompanying Sequence Listing under 37 CFR 1.821-1.825 (2 pages);

5. 3.5 inch disk containing Computer-Readable form of Sequence Listing:

6. Application Fee (check for \$824.00);

7. Return Postcard

are/is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Jesus R. Remedios

(Typed or printed name of person mailing papers(s) and/or fee)

(Signature of person mailing paper(s) and/or fee)

Mailing Address:

MORGAN & FINNEGAN, L.L.P. 345 Park Avenue New York, NY 10154-0053 (212) 758-4800 Telephone (212) 751-6849 Facsimile

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: D0034np

In re patent application of

BOWEN, MICHAEL A. et al.

Serial No. Unassigned

Filed: Concurrently Herewith

For: POLYNUCLEOTIDE ENCODING AN ACTIVATED HUMAN T-LYMPHOCYTE-DERIVED

PROTEIN RELATED TO UBIQUITIN CONJUGATING ENZYME

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents Washington, D.C. 20231
Box SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

- 1. . the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include new matter;
- 2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same; and
 - 3. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United



States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

Date

HARBOR CONSULTING
Intellectual Property Services
1500A Lafayette Road
Suite 262
Portsmouth, N.H.
800-318-3021

2